Skip to main content
About
Research and Development
CPI-613
®
(devimistat)
CB-839 (telaglenastat)
Pipeline
Leadership
Executive Management
Board of Directors
Medical Advisors
Scientific Advisors
Clinical Trial Enrollment
Contact Us
News & Investors
Press Releases
News Coverage
Investor/Media Kit
Request Information
Scientific Exchange
Publications
Conference Presentations
Work With Us
Partnering
Careers
Culture
Compassionate Use
Clinical Trial Enrollment
Contact Us
Investor/Media Kit
Investor/Media Kit Materials
Executive Management Bios
Cornerstone Pharma CPI-613 Factsheet
Cornerstone Pharma CB-839 Factsheet
